BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30664963)

  • 1. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
    Gomes S; Raimundo L; Soares J; Loureiro JB; Leão M; Ramos H; Monteiro MN; Lemos A; Moreira J; Pinto M; Chlapek P; Veselska R; Sousa E; Saraiva L
    Cancer Lett; 2019 Apr; 446():90-102. PubMed ID: 30664963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK; Findley HW
    Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Al-Ghabkari A; Narendran A
    Cancer Biother Radiopharm; 2019 May; 34(4):252-257. PubMed ID: 30724592
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
    Lemos A; Gomes AS; Loureiro JB; Brandão P; Palmeira A; Pinto MMM; Saraiva L; Sousa ME
    Molecules; 2019 May; 24(10):. PubMed ID: 31121972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
    Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
    Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
    [No Abstract]   [Full Text] [Related]  

  • 9. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
    PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
    Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
    Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells.
    Dabiri Y; Kalman S; Gürth CM; Kim JY; Mayer V; Cheng X
    Sci Rep; 2017 Jul; 7(1):5423. PubMed ID: 28710427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
    Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
    Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
    Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway.
    Wang J; Xie H; Gao F; Zhao T; Yang H; Kang B
    Tumour Biol; 2016 Mar; 37(3):4203-12. PubMed ID: 26490992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribosomal proteins L11 and L5 activate TAp73 by overcoming MDM2 inhibition.
    Zhou X; Hao Q; Zhang Q; Liao JM; Ke JW; Liao P; Cao B; Lu H
    Cell Death Differ; 2015 May; 22(5):755-66. PubMed ID: 25301064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.